{
  "schemaVersion": 1,
  "id": "research-058",
  "slug": "058-what-the-japan-and-taiwan-cagrisema-trial-adds-to-the-evidence",
  "title": "What the Japan and Taiwan CagriSema trial adds to the evidence",
  "catalogLabel": "Cagrilintide",
  "productCollection": "https://heritagebiolabs.com/research-library/products/cagrilintide",
  "productHandles": [
    "cagrilintide-701"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/cagrilintide-701"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 392,
  "sourceYears": [
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids linked by peptide bonds. Different peptides can engage different receptors that influence hunger and fullness. Cagrilintide is a long-acting investigational amylin-based peptide. CagriSema pairs it with the GLP-1 receptor agonist semaglutide. In REDEFINE 5, researchers examined whether the combination produced a different weight change from semaglutide alone in adults studied in Japan and Taiwan. [1]",
    "The trial recruited at 21 sites in Japan and one site in Taiwan. It enrolled adults with excess body weight and obesity-related complications under the eligibility criteria described in the report. Of 331 participants who were randomized, about a quarter had type 2 diabetes. The investigators assigned people to the fixed combination or to semaglutide alone, with lifestyle support in both groups. The comparison was double-blind, meaning participants and the staff involved in the study were masked to which active treatment was assigned. [1]",
    "At 68 weeks, the estimated mean weight change was −18.4% with the combination and −11.9% with semaglutide. The primary analysis estimated outcomes under an assumption that participants took the assigned treatment as intended. When the weight at the main time point was missing, researchers used a statistical method to estimate the missing measurement for analysis. This approach answers a specific question about the effect under the defined treatment assumptions. The same paper also reports that 10% discontinued the combination and 6% discontinued semaglutide. Reading those details helps put the average estimates in context. [1]",
    "Gastrointestinal events were the most common adverse events in both groups. This matters when evaluating a weight-management trial. The main outcome indicates the direction and size of the average weight difference, and the adverse-event and discontinuation data describe other parts of the experience. Neither average captures the result of every participant. [1]",
    "The study extends the combination evidence to a population enrolled in an East Asian setting with specified eligibility criteria and background care. Geography alone does not tell us how a person would respond. The study’s mix of diabetes status, the definition of obesity-related complications, and the way outcomes were analyzed all shape what can be inferred. Since the comparison was the combination versus semaglutide, it provides evidence for adding cagrilintide within that fixed product. It does not show what would have happened in a separate cagrilintide-only group. That question belongs to trials that assign people to cagrilintide by itself. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Toshimasa Yamauchi et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology (publication 2026-04-17).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42009015/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/058-what-the-japan-and-taiwan-cagrisema-trial-adds-to-the-evidence",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/058-what-the-japan-and-taiwan-cagrisema-trial-adds-to-the-evidence.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/058-what-the-japan-and-taiwan-cagrisema-trial-adds-to-the-evidence.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 012 - Cagrilintide.docx",
    "sourceArticleNumber": 58,
    "contentSha256": "e4cdf1c560c8c4cf290b48daba18ac09ee5cae32509af5cbd07e99ff91a0a172",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
